Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 2, 1997, Pages 473-478

  Ahrén, Bo ^a,c   Larsson, Hillevi ^a   Holst, Jens J ^b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PEPTIDES;

EID: 0031032244     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.2.473     Document Type: Article

References (37)

1. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF. 1986 Proglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem. 261:11880-11889.
2. Kreymann B, Williams G, Ghatei MA, Bloom SR. 1987 Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 2:1300-1303.
3. Ørskov C. 1992 Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia. 35:701-711.
4. Fehmann HC, Göke R, Göke B. 1995 Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev. 16:390-410.
5. Holst JJ, Ørskov C, Schwartz TW, Nielsen OV. 1987 Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 211:169-174.
6. (7-36)amide: influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas. 6:208-215.
7. Gutniak MK, Ørskov C, Holst JJ, Ahrén B, Efendic S. 1992 Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 326:1316-1322.
8. Nathan DM, Schreiber E, Mojsov S, Habener JF. 1992 Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care. 15:270-276.
9. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. 1994 Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest. 93:2263-2266.
10. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. 1994 The insulinotropic actions of glucose-dependent insulinotyropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept. 51:63-74.
11. Ahrén B. 1995 Insulinotropic action of truncated glucagon-like peptide-1 in mice. Acta Physiol Scand. 153:205-206.
12. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W. 1995 Insulinotropic actions of intravenous glucagon-like peptide-1 (7-36) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol. 32:13-16.
13. Hargrove DM, Nardone NA, Persson LM, Parker JC, Stevenson RW. 1995 Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short or long-term administration. Metabolism. 44:1231-1237.
14. Gutniak MK, Linde B, Holst JJ, Efendic S. 1994 Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care. 17:1039-1044.
15. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. 1993 Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 36:741-744.
16. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA. 1996 Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 81:327-332.
17. Porte, Jr, D. 1991 B cells in type 2 diabetes mellitus. Diabetes. 40:166-180.
18. DeFronzo RA, Bonadonna RC, Ferrannini E. 1992 Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 15:318-368.
19. Martín BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. 1992 Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 2:925-929.
20. Lillioja S, Mott DM, Howard BV, et al. 1988 Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med. 318:1217-1225.
21. O'Rahilly SP, Rudenski AS, Burnett MA, Nugent Z, Hosker JP, Darling P. 1986 Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial type 2 diabetes. Lancet. 2:360-364.
22. Dimitriadis GD, Pekling GB, Gerich JE. 1985 Abnormal glucose modulation of islet A- and B-cell responses to arginine in non-insulin-dependent diabetes mellitus. Diabetes. 34:541-547.
23. Yki-Järvinen H. 1995 Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia. 38:1378-1388.
24. Baron AD, Shaeffer L, Shragg P, Kolterman OG. 1987 Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes. 36:274-283.
25. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte, Jr, D. 1984 Diminished B cell secretory capacity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 74:1318-1328.
26. DeFronzo RA, Tobin JD, Andres R. 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J Physiol. 237:E214-E223.
27. Cerasi E. 1975 Potentiation of insulin release by glucose in man. Acta Endocrinol. 79:511-534.
28. Grill V. 1981 Time and dose dependencies for priming effect of glucose on insulin secretion. Am J Physiol. 240:E24-E31.
29. Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ. 1994 Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes. 43:535-539.
30. Norusis MJ. 1992 SPSS for Windows. Base System User's Guide, Release 5.0. Chicago: SPSS Inc.
31. Rachman J, Turner RC. 1995 Drugs on the horizon for treatment of type 2 diabetes. Diabet Med. 12:467-478.
32. Habener JF. 1993 The incretin notion and its relevance to diabetes. Endocrinol Metab Clin North Am. 22:775-794.
33. Larsson H, Berglund G, Ahrén B. 1995 Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. J Clin Endocrinol Metab. 80:1778-1782.
34. Hvidberg A, Toft Nielsen M, Hilsted J, Ørskov C, Holst JJ. 1994 Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism. 43:104-108.
35. DeFronzo RA, Simonson D, Ferrannini E. 1982 Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 23:313-319.
36. Horwitz DL, Starr JI, Mako ME, et al. 1975 Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest. 55:1278-1283.
37. Argoud GM, Schade DS, Eaton RP. 1987 Insulin suppresses its own secretion in vivo. Diabetes. 36:959-962.